Key clinical point: Minodronate demonstrated better efficacy than alendronate, risedronate, raloxifene, or eldecalcitol in patients with osteoporosis.
Major finding: Compared with other drugs, minodronate significantly decreased N-telopeptide of type I collagen/creatinine (weighted mean difference [WMD], −13.669; 95% confidence interval [CI], −23.108 to −4.229), bone alkaline phosphatase (WMD, −1.26; 95% CI: −2.04 to −0.47), and tartrate-resistant acid phosphatase 5b (WMD, −154.11; 95% CI, −277.85 to −30.37).
Study details: A meta-analysis of 13 randomized controlled trials including 3,740 patients with osteoporosis.
Disclosures: This study received no financial support. The authors declared no conflicts of interest.
Citation: Liu Q et al. 2020 Oct 2. doi: 10.1097/MD.0000000000022542 .